论文部分内容阅读
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multi
【作 者】
：
【机 构】
：
Cancer Hospital and Institute, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sc
【出 处】
：
2015年北京放射肿瘤年会
【发表日期】
：
2016年5期
其他文献
Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal c
Background: In recent years, chemotherapy, radiotherapy, and targeted drugs have been respectively used in nasopharyngeal carcinoma.In our research, we combined all of them for better curative effects
盐酸羟考酮缓释片作为一种新型的强阿片类镇痛药,镇痛效果确切、口服安全性高、不良反应轻微,持续应用可提高癌痛患者的生存质量,是临床治疗中重度癌痛的首选药物之一.针对盐酸羟考酮缓释片治疗癌痛的药理特点,近年国内外将其用于癌痛治疗过程中的剂量调整,取得了很好的效果.
Concurrent Chemotherapy for Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulate
Objective To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT).Methods From July 2004 to June 2011,180 non-metast
会议
本研究主要是评价接受根治性切除和辅助化疗的pⅢA-N2期非小细胞肺癌(NSCLC)患者,进一步接受术后三维适形放疗(3DCRT)对生存和复发模式的影响.从2009.1.1到2013.5.31,所有患者均接受根治性肺叶切除的pⅢA-N2NSCLC患者在完成4周期以顺铂为基础的联合化疗后进行全面复查,未出现肿瘤复发转移的患者被随机分入术后放疗(PORT)组和对照组.入组≥2年的患者纳入本次分析.POR
分析Ⅳ期肺腺癌采用选择性放疗联合/或靶向治疗的疗效.分析本院2009年6月1日起,Ⅳ期肺腺癌接受肺原发病灶和关键转移病灶选择性放疗联合/或靶向治疗的患者共50例,其中单纯应用小分子靶向药物(表皮生长因子受体酪氨酸激酶抑制剂,EGFR-TKI)7例,单纯选择性放疗患者18例,选择性放疗联合EGFR-TKI25例.小分子靶向药物使用时间1～44月,中位时间14月.放疗方案为：体部伽马刀技术,70％等剂
Objective: To evaluate the long-term survival outcomes and toxicity of a larger series of patients with non-metastatic T4 classification nasopharyngeal carcinoma (NPC) treated with intensity-modulated
Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluat
For patients with locoregionally advanced nasopharyngeal carcinoma (NPC), radiotherapy, chemotherapy and even targeted therapy are widely accepted treatments.These treatments, although they mostly ach
Background.The purpose of this study was to determine the features of the eldedy patient with nasopharyngeal carcinoma (NPC).Methods.The medical records of 212 patients with NPC, aged >65 years, and r